Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Feasibility Study of Sequential Hepatic Internal Radiation and Systemic Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastatic to Liver.

NCT02913417 is registered in ClinicalTrials.gov with David Minor, MD as lead sponsor.

NCT NCT02913417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02913417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Feasibility Study of Sequential Hepatic Internal Radiation and Systemic Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastatic to Liver.
Lead sponsor
David Minor, MD
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 10, 2016
Completion date
June 30, 2023
Enrollment
26 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic metastases, uveal melanoma